Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10666513 | 0.87 | MIF (0.50) | LMNACYP3A4ACHEPARP1MEN1 | |
| SCHEMBL29262825 | 0.85 | KMT2A (0.56) | LMNAACHEMEN1KMT2A | |
| Acetone SCHEMBL28493231 | 0.82 | NOS2 (0.43) | CYP3A4 | |
| SCHEMBL4672 | 0.81 | TAAR1 (0.50) | ACHE | |
| SCHEMBL7989550 | 0.80 | CYP3A4 (0.54) | LMNACYP3A4ACHEPARP1MEN1 | |
| SCHEMBL3407357 | 0.79 | CYP3A4 (0.58) | LMNACYP3A4ACHEPARP1MEN1 | |
| SCHEMBL9362791 | 0.77 | CYP3A4 (0.59) | LMNACYP3A4ACHEPARP1MEN1 | |
| SCHEMBL202980 | 0.77 | CYP3A4 (0.59) | LMNACYP3A4ACHEPARP1MEN1 | |
| SCHEMBL3339215 | 0.77 | CYP3A4 (0.59) | LMNACYP3A4ACHEPARP1MEN1 | |
| SCHEMBL31525960 | 0.77 | CYP3A4 (0.59) | LMNACYP3A4ACHEPARP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491741-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050080119-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2005-04-14 | — | — | US | disclosed |
| US-6803384-B2 | FOR THERAPY OF REPERFUSION INJURY | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| EP-1005445-B1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-1403247-A1 | N-Alkanoylphenylalanine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20040006236-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2004-01-08 | — | — | US | disclosed |
| US-6515124-B2 | (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis | HOFFMAN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1261579-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20020161237-A1 | Dehydroamino acids | HOFFMANN-LA ROCHE INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020052512-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2002-05-02 | — | — | US | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| EP-1121342-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000021920-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161237-A1 | Dehydroamino acids | HSD3B1, CYP8B1, TH | LMNA 4331/4885CYP3A4 410/4885ACHE 4866/4885 |
| US-20040006236-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | LMNA 3239/4885CYP3A4 2684/4885ACHE 3769/4885 |
| US-20020052512-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | LMNA 3239/4885CYP3A4 2684/4885ACHE 3769/4885 |
| US-20070155671-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | LMNA 2978/4885CYP3A4 3109/4885ACHE 3960/4885 |
| US-20050080119-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | LMNA 2978/4885CYP3A4 3109/4885ACHE 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.